NCT02164812View on ClinicalTrials.gov

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
HIV/AIDS
Interventions
DRUG

Moxifloxacin

DRUG

Placebo

DRUG

Efavirenz

Trial Locations (1)

21225

Parexel International - Baltimore Epcu, Baltimore

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY